This special edition features upcoming oral presentations by MD Anderson researchers at the 2023 European Society for Medical Oncology (ESMO) Congress focused on clinical advances across a variety of cancer types.
Tag: EGFR-mutant lung cancer
MD Anderson EGFR Classification licensed by BostonGene and Tempus to provide new insight on atypical mutations in lung cancer
MD Anderson announced licensing agreements with BostonGene and Tempus for the MD Anderson EGFR Classification, which organizes EGFR mutations into subgroups that may guide clinical decision-making.